An interventional study of Evaluation of muscle dysfunction in intensive care units for septic schock patients in Septic Shock, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.
Among the 184 studies in Shock, Septic with a site in France, this one is the 38th largest by planned enrollment of the 105 interventional ones that give a count, is one of 17 that started in 2026, is one of 52 with no phase, reaches primary completion later than 47 of the 49 other live ones, and was the 177th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre National de la Recherche Scientifique, France · Sites in France
Ages 18–49 · Women only · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 19 · Phase 3 32 · Phase 4 9
First in 1997; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 196 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 120 across the 105 interventional studies, 100 across the 79 observational. Of the 108 that completed or were terminated, 6 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 184 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.
Centre Hospitalier Universitaire de Saint Etienne has 3 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
13 of the studies in Shock, Septic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04748796Phase 3Centre Hospitalier Universitaire, AmiensComparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility | 2027-06 |
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT04067674Hospices Civils de LyonSeptic Shock-induced Immunosuppression | 2026-11-21 |
| NCT07354568Centre Hospitalier Universitaire, AmiensPrognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock | 2027-01-01 |
| NCT07199998Centre National de la Recherche Scientifique, FranceImpact of Internal Menstrual Protections on Immunity and Vaginal Microbiota | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 184 studies in Shock, Septic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Muscle dysfunction in intensive care units is associated with significant morbidity and mortality. During septic shock, there is an increased catabolism and systemic inflammation resulting in quantitative and qualitative muscle impairment. In the intensive care setting, quantitative and qualitative assessment of muscle function is challenging due to critical care environments (general anesthesia, altered consciousness, etc.). CT scan measurement at the 3rd lumbar level has been proposed to evaluate muscle function. Recent retrospective studies have highlighted increased mortality among patients with muscle mass impairment and/or decreased muscle density.
To date, no prospective study has assessed the prognostic value of CT scan measurements of muscle function upon admission to intensive care units for patients treated for septic shock. That is the aim of this project.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients hospitalized in intensive care for septic shock defined by the presence of a documented or suspected infection, plasma lactate >2 mmol/L, and an increase in SOFA score of more than 2 points from baseline (Singer et al., 2016)
Exclusion Criteria:
Evaluation of muscle dysfunction in intensive care units for septic shock patients
Other: Evaluation of muscle dysfunction in intensive care units for septic schock patients
Correlation between muscle L3 CT scan muscle derived parameters of muscle function upon intensive care unit admission and 3 months mortality after ICU discharge for patients admitted for septic shock
vital status
alive or dead
Time frame: 90 days
Total muscle mass measured at L3 (cm²/m² )
Total muscle mass measured at L3 by CT scan, normalized by patient height (Skeletal Muscle Index), in cm²/m² upon admission to the ICU (Correlation between three L3 CT scan parameters of muscle function upon admission to the intensive care unit and the risk of mortality at 3 months after ICU discharge in septic shock patients).
Time frame: at inclusion
Total muscle density measured at L3 ( Hounsfield Unit)
\- Total muscle density measured at L3 by CT scan (Skeletal Muscle Density) in HU upon admission to the ICU (Correlation between three L3 CT scan parameters of muscle function upon admission to the intensive care unit and the risk of mortality at 3 months after ICU discharge in septic shock patients).
Time frame: at inclusion
Total fat excretion fraction measured at L3 (%)
Total fat excretion fraction measured at L3 (Fat Fraction) by CT scan upon admission to the ICU (Correlation between three L3 CT scan parameters of muscle function upon admission to the intensive care unit and the risk of mortality at 3 months after ICU discharge in septic shock patients).
Time frame: at inclusion
SOFA (Sequential Organ Failure Assessment) severity score
minimum=0, maximum=3 (Worse score)
Time frame: at inclusion, 10 days.
Kinetics of changes in muscle assessment
To assess the kinetics of changes in muscle scan parameters and muscle function.
Time frame: Day 1, 10, 90
Total fat excretion fraction measured at L3 (%)
Evolution of the total fat excretion fraction measured at L3 (Fat Fraction) by CT scan at inclusion, 10 days and 90 days.
Time frame: at inclusion, 10 days, 90 days
Total muscle density measured at L3 ( Hounsfield Unit)
Evolution of total muscle density measured at L3 by CT scan (Skeletal Muscle Density) in HU upon inclusion, 10 days, 90 days
Time frame: at inclusion, 10 days, 90 days
Total muscle mass measured at L3 (cm²/m² )
Evolution of the total muscle mass measured at L3 by CT scan, normalized by patient height (Skeletal Muscle Index), in cm²/m² upon inclusion, 10 days, 90 days.
Time frame: at inclusion, 10 days, 90 days
MRC score (Medical Research Council)
Minimum=0 (worse score), Maximum=5
Time frame: at discharge from intensive care, 90 days
Handgrip test (Kg)
Time frame: at discharge from intensive care, 90 days
Started Mar 2026 (actual). Primary completion is estimated for May 2030, 49 months after the start.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 49 months is above that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Saint Etienne →